Advancing cancer drug discovery towards more agile development of targeted combination therapies

Area of Science:

• Oncology
• Drug Discovery
• Systems Biology

Background:

• Current drug discovery relies on target-centric approaches, screening large libraries against specific targets.
• High attrition rates in clinical development indicate limitations of monotherapies for solid tumors.
• Cancer cells can subvert single-agent therapies by exploiting complex biological networks.

Purpose of the Study:

• To address the limitations of conventional drug discovery for developing effective combination therapies.
• To highlight emerging technologies that enable a more agile and systems-level approach to drug discovery.
• To facilitate the rational design, validation, and clinical development of novel drug combinations for cancer treatment.

Main Methods:

• Review of emerging technologies supporting a less reductionist drug discovery approach.
• Focus on identifying and retargeting biological networks that enable cancer cell resistance.
• Emphasis on rational design and validation of drug combinations.

Main Results:

• Current target-centric strategies are suboptimal for developing combination therapies.
• Emerging technologies offer a more agile approach to drug discovery and development.
• A systems-level understanding of cancer biology is crucial for effective combination therapy design.

Conclusions:

• A paradigm shift from reductionist to systems-level, agile drug discovery is needed for combination therapies.
• Emerging technologies can support the rational development of novel drug combinations.
• Retargeting cancer's adaptive resistance mechanisms is essential for improving treatment efficacy.